It has been reported that hypertension development predicted a better response of the tumor to the therapy with anti-VEGF drugs in some studies [32, 117, 118], therefore, in a case of either hypertension de novo or worsening of the preexisting hypertension, physicians should maintain targeted therapy and use of hypotensive medications to control blood pressure rather than withdraw antineoplastic drugs. This evidence concerns the gene VEGFA and Hypertension.